(Adnkronos) – “Compared to the past, there are therapeutic proposals capable of treating even severe psoriasis, but many people do not know it. Our association has the duty to inform patients”. This is what Valeria Corazza, president of the Association of Italian Psoriasis Friends of the Corazza Foundation – ApiaFCo, said during the press conference organized by Bristol Myers Squibb to announce the green light from Aifa to the reimbursement of deucravacitinib for the treatment of moderate to severe psoriasis.
#Psoriasis #Corazza #Apiafco #Research #continues #information #lacking
Psoriasis, Corazza (Apiafco): “Research continues, but information is lacking”
